Testosterone and benign prostatic hyperplasia

Asian Journal of Andrology

Volumn 17, Issue 2, 2015, Pages 212-216

  Jarvis, Thomas R ^a   Chughtai, Bilal ^a   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

benign prostatic hyperplasia; lower urinary tract symptoms; metabolic syndrome X; testosterone; urinary bladder neck obstruction

Indexed keywords

ANDROSTANOLONE; TESTOSTERONE;

AGING; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; CLINICAL EXAMINATION; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTOSTERONE BLOOD LEVEL; URINE RETENTION; ADVERSE EFFECTS; AGE; DEFICIENCY; EUNUCHISM; HORMONE SUBSTITUTION; LOWER URINARY TRACT SYMPTOMS; MALE; METABOLISM; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

AGE FACTORS; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

EID: 84924738251     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.140966     Document Type: Review

References (51)

1. Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013; 31: 103-25.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
3. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest 2014.
4. Berry SJ, Coffey DS, Strandberg JD, Ewing LL. Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia. Prostate 1986; 9: 295-302.
5. Sasagawa I, Nakada T, Kazama T, Satomi S, Terada T, et al. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Int Urol Nephrol 1990; 22: 279-84.
6. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011; 82: 184-99.
7. Wilson JD. Recent studies on the mechanism of action of testosterone. N Engl J Med 1972; 287: 1284-91.
8. Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 2008; 180: 1030-2.
9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-31.
10. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: festimates from the massachusetts male aging study. J Clin Endocrinol Metab 2004; 89: 5920-6.
11. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-9.
12. Liu CC, Huang SP, Li WM, Wang CJ, Chou YH, et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 2007; 70: 677-80.
13. Isaacs JT, Coffey DS. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 1981; 108: 445-53.
14. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: arandomized controlled trial. JAMA 2006; 296: 2351-61.
15. Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int 2010; 106: 1700-3.
16. Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99-106.
17. Dohle DR, Arver S, Bettocchi C, Kliesch S, Punab M, et al. Guidelines on Male Hypogonadism. Uroweb 2012. Available from: http://www.uroweb.org/guidelines/online-guidelines. [Last accessed on 2014 Aug 18].
18. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
19. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013; 10: 245-84.
20. Liverman CT, Blazer DG, eds. Testosterone and Aging: Clinical Research Directions. The National Academies Press, Washington DC; 2004.
21. Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 2013; 82: 321-6.
22. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994; 40: 341-9.
23. Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int 2013; 111: 880-90.
24. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113-20.
25. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001; 54: 437-45.
26. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20.
27. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med 2013; 10: 2518-28.
28. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397-402.
29. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 121: 755-60.
30. Roehrborn CG, Kaplan SA, Noble WD, Lucia MS, Slawin KM, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPE: results from the MTOPS study. In: proceedings From the Annual Meeting of the American Urological Association. San Antonio, TX, USA; 2005.
31. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the reduce trial. Eur Urol 2008; 54: 1379-84.
32. Maserejian NN, Chen S, Chiu GR, Araujo AB, Kupelian V, et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J Urol 2014; 191: 107-13.
33. Walther HW, Willoughby RM. Hormonal treatment of benign prostatic hyperplasia. J Urol 1938; 40: 135-44.
34. Pearl JA, Berhanu D, Franc¸ois N, Masson P, Zargaroff S, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol 2013; 190: 1828-33.
35. Yassin DJ, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 2014; 32: 1049-54.
36. Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health 2013; 31: 47-52.
37. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011; 14: 53-8.
38. Park YW, Kim SB, Kwon H, Kang HC, Cho K, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013; 82: 674-9.
39. Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013; 81: 1325-9.
40. Antunes AA, Araújo LH, Nakano E, Muracca E, Srougi M. Obesity may influence the relationship between sex hormones and lower urinary tract symptoms. Int Braz J Urol 2014; 40: 240-6.
41. Selice R, Caretta N, Di Mambro A, Torino M, Palego P, et al. Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. Eur J Endocrinol 2013; 169: 743-9.
42. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012; 212: 71-84.
43. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013; 73: 1391-402.
44. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014; 83: 167-73.
45. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - Focus on the UK. BJU Int 2014.
46. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014; 11: 1567-76.
47. Takao T, Tsujimura A, Nakayama J, Matsuoka Y, Miyagawa Y, et al. Lower urinary tract symptoms after hormone replacement therapy in Japanese patients with late-onset hypogonadism: a preliminary report. Int J Urol 2009; 16: 212-4.
48. Kaplan SA, Lee JY, O'Neill EA, Meehan AG, Kusek JW. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 2013; 16: 169-72.
49. Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, et al. The laboratory diagnosis of testosterone deficiency. Urology 2014; 83: 980-8.
50. Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 2014; 99: 835-42.
51. Kaplan SA. Re: relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. J Urol 2011; 186: 1983-4.